메뉴 건너뛰기




Volumn 124, Issue 4, 2012, Pages 33-40

Exenatide once weekly for the treatment of type 2 diabetes mellitus: Clinical results in subgroups of patients using different concomitant medications

Author keywords

Concomitant treatment; Diabetes; Exenatide once weekly; GLP 1

Indexed keywords

EXENDIN 4; GLITAZONE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; LIPID; METFORMIN; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT; PEPTIDE; VENOM;

EID: 84871697848     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2012.07.2568     Document Type: Article
Times cited : (10)

References (27)
  • 1
    • 33644618433 scopus 로고    scopus 로고
    • The biology of incretin hormones
    • Drucker DJ. The biology of incretin hormones. Cell Metab. 2006; 3(3):153-165.
    • (2006) Cell Metab , vol.3 , Issue.3 , pp. 153-165
    • Drucker, D.J.1
  • 2
    • 35748957503 scopus 로고    scopus 로고
    • The physiology of glucagon-like peptide 1
    • Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87(4):1409-1439.
    • (2007) Physiol Rev , vol.87 , Issue.4 , pp. 1409-1439
    • Holst, J.J.1
  • 3
    • 3242730474 scopus 로고    scopus 로고
    • Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans
    • Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab. 2004;287(2):E199-E206.
    • (2004) Am J Physiol Endocrinol Metab , vol.287 , Issue.2
    • Holst, J.J.1    Gromada, J.2
  • 4
    • 0023758530 scopus 로고
    • Nielsen OV Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach
    • Orskov C, Holst JJ, Nielsen OV Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology. 1988;123(4):2009-2013.
    • (1988) Endocrinology , vol.123 , Issue.4 , pp. 2009-2013
    • Orskov, C.1    Holst, J.J.2
  • 5
    • 0036959991 scopus 로고    scopus 로고
    • Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers
    • Nauck MA, Heimesaat MM, Behle K, et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab. 2002;87(3):1239-1246.
    • (2002) J Clin Endocrinol Metab , vol.87 , Issue.3 , pp. 1239-1246
    • Nauck, M.A.1    Heimesaat, M.M.2    Behle, K.3
  • 6
    • 0030667056 scopus 로고    scopus 로고
    • Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans
    • Nauck MA, Niedereichholz U, Ettler R, et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol. 1997;273(5 pt 1):E981-E988.
    • (1997) Am J Physiol , vol.273 , Issue.5 PART 1
    • Nauck, M.A.1    Niedereichholz, U.2    Ettler, R.3
  • 7
    • 0029859220 scopus 로고    scopus 로고
    • Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats
    • Tang-Christensen M, Larsen PJ, Göke R, et al. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol. 1996;271(4 pt 2):R848-R856.
    • (1996) Am J Physiol , vol.271 , Issue.4 PART 2
    • Tang-Christensen, M.1    Larsen, P.J.2    Göke, R.3
  • 8
    • 79956336447 scopus 로고    scopus 로고
    • Effect of exenatide on splanchnic and peripheral glucose metabolism in type 2 diabetic subjects
    • Cersosimo E, Gastaldelli A, Cervera A, et al. Effect of exenatide on splanchnic and peripheral glucose metabolism in type 2 diabetic subjects. J Clin Endocrinol Metab. 2011;96(6):1763-1770.
    • (2011) J Clin Endocrinol Metab , vol.96 , Issue.6 , pp. 1763-1770
    • Cersosimo, E.1    Gastaldelli, A.2    Cervera, A.3
  • 9
    • 45549101449 scopus 로고    scopus 로고
    • Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes
    • Cervera A, Wajcberg E, Sriwijitkamol A, et al. Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. Am J Physiol Endocrinol Metab. 2008;294(5):E846-E852.
    • (2008) Am J Physiol Endocrinol Metab , vol.294 , Issue.5
    • Cervera, A.1    Wajcberg, E.2    Sriwijitkamol, A.3
  • 10
    • 0038497464 scopus 로고    scopus 로고
    • Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes
    • Kolterman OG, Buse JB, Fineman MS, et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2003;88(7):3082-3089.
    • (2003) J Clin Endocrinol Metab , vol.88 , Issue.7 , pp. 3082-3089
    • Kolterman, O.G.1    Buse, J.B.2    Fineman, M.S.3
  • 11
    • 0033151448 scopus 로고    scopus 로고
    • Factors affecting the degradation rate of poly (lactide-co-glycolide) microspheres in vivo and in vitro
    • Tracy MA, Ward KL, Firouzabadian L, et al. Factors affecting the degradation rate of poly (lactide-co-glycolide) microspheres in vivo and in vitro. Biomaterials. 1999;20(11):1057-1062.
    • (1999) Biomaterials , vol.20 , Issue.11 , pp. 1057-1062
    • Tracy, M.A.1    Ward, K.L.2    Firouzabadian, L.3
  • 12
    • 80052731231 scopus 로고    scopus 로고
    • Encapsulation of exenatide in poly-(D, L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes
    • DeYoung MB, MacConell L, Sarin V, Trautmann M, Herbert P. Encapsulation of exenatide in poly-(D, L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. Diabetes Technol Ther. 2011;13(11):1145-1154.
    • (2011) Diabetes Technol Ther , vol.13 , Issue.11 , pp. 1145-1154
    • Deyoung, M.B.1    Macconell, L.2    Sarin, V.3    Trautmann, M.4    Herbert, P.5
  • 13
    • 79960952161 scopus 로고    scopus 로고
    • AACE Task Force for Developing a Diabetes Comprehensive Care Plan. American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan: Executive summary
    • Handelsman Y, Mechanick JI, Blonde L, et al; AACE Task Force for Developing a Diabetes Comprehensive Care Plan. American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan: executive summary. Endocr Pract. 2011;17(2):287-302.
    • (2011) Endocr Pract , vol.17 , Issue.2 , pp. 287-302
    • Handelsman, Y.1    Mechanick, J.I.2    Blonde, L.3
  • 14
    • 84866268783 scopus 로고    scopus 로고
    • Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
    • Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364-1379.
    • (2012) Diabetes Care , vol.35 , Issue.6 , pp. 1364-1379
    • Inzucchi, S.E.1    Bergenstal, R.M.2    Buse, J.B.3
  • 15
    • 53249142132 scopus 로고    scopus 로고
    • Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: A randomised, open-label, non-inferiority study
    • DURATION-1 Study Group
    • Drucker D, Buse JB, Taylor K, et al; DURATION-1 Study Group. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008;372(9645):1240-1250.
    • (2008) Lancet , vol.372 , Issue.9645 , pp. 1240-1250
    • Drucker, D.1    Buse, J.B.2    Taylor, K.3
  • 16
    • 77955573674 scopus 로고    scopus 로고
    • Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): A randomised trial
    • DURATION-2 Study Group
    • Bergenstal RM, Wysham C, MacConell L, et al; DURATION-2 Study Group. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet. 2010;376(9739):431-439.
    • (2010) Lancet , vol.376 , Issue.9739 , pp. 431-439
    • Bergenstal, R.M.1    Wysham, C.2    Macconell, L.3
  • 17
    • 77953859640 scopus 로고    scopus 로고
    • Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): An open-label randomised trial
    • Diamant M, Van Gaal L, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet. 2010;375(9733):2234-2243.
    • (2010) Lancet , vol.375 , Issue.9733 , pp. 2234-2243
    • Diamant, M.1    van Gaal, L.2    Stranks, S.3
  • 18
    • 84859013614 scopus 로고    scopus 로고
    • Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naïve patients with type 2 diabetes (DURATION-4): A 26-week, double-blind study
    • DURATION-4 Study Group
    • Russell-Jones D, Cuddihy RM, Hanefeld M, et al; DURATION-4 Study Group. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naïve patients with type 2 diabetes (DURATION-4): a 26-week, double-blind study. Diabetes Care. 2012;35(2):252-258.
    • (2012) Diabetes Care , vol.35 , Issue.2 , pp. 252-258
    • Russell-Jones, D.1    Cuddihy, R.M.2    Hanefeld, M.3
  • 19
    • 79955661908 scopus 로고    scopus 로고
    • DURATION-5: Exenatide once weekly resulted in greater improvements in glycemic control compared to exenatide twice daily in patients with type 2 diabetes
    • Blevins T, Pullman J, Malloy J, et al. DURATION-5: Exenatide once weekly resulted in greater improvements in glycemic control compared to exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011;96(5):1301-1310.
    • (2011) J Clin Endocrinol Metab , vol.96 , Issue.5 , pp. 1301-1310
    • Blevins, T.1    Pullman, J.2    Malloy, J.3
  • 20
    • 84857385645 scopus 로고    scopus 로고
    • Efficacy and safety of exenatide once weekly versus liraglutide in subjects with type 2 diabetes (DURATION-6): A randomised, open-label study [abstract 75]
    • Buse B, Nauck MA, Forst T, et al. Efficacy and safety of exenatide once weekly versus liraglutide in subjects with type 2 diabetes (DURATION-6): a randomised, open-label study [abstract 75]. Diabetologia. 2011;54(suppl 1):S38.
    • (2011) Diabetologia , vol.54 , Issue.SUPPL. 1
    • Buse, B.1    Nauck, M.A.2    Forst, T.3
  • 21
    • 84887412474 scopus 로고    scopus 로고
    • Efficacy and safety of exenatide once weekly versus exenatide twice daily in patients of Pan-Asian descent with type 2 diabetes
    • Ji LN, Onishi Y, Woo AC, et al. Efficacy and safety of exenatide once weekly versus exenatide twice daily in patients of Pan-Asian descent with type 2 diabetes. World Diabetes Congress Abstract Book. 2011; P1144.
    • (2011) World Diabetes Congress Abstract Book
    • Ji, L.N.1    Onishi, Y.2    Woo, A.C.3
  • 22
    • 84876524541 scopus 로고    scopus 로고
    • BYDUREON™ (exenatide extended-release for injectable suspension) [package insert]. San Diego, CA: Amylin Pharmaceuticals, Inc
    • BYDUREON™ (exenatide extended-release for injectable suspension) [package insert]. San Diego, CA: Amylin Pharmaceuticals, Inc.; 2012.
    • (2012)
  • 23
    • 0033578476 scopus 로고    scopus 로고
    • Pharmacologic therapy for type 2 diabetes mellitus
    • DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 1999;131(4):281-303.
    • (1999) Ann Intern Med , vol.131 , Issue.4 , pp. 281-303
    • Defronzo, R.A.1
  • 24
    • 16344382941 scopus 로고    scopus 로고
    • Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: A randomized, comparative study
    • Matthews DR Charbonnel BH, Hanefeld M, Brunetti P, Schernthaner G. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes Metab Res Rev. 2005;21(2):167-174.
    • (2005) Diabetes Metab Res Rev , vol.21 , Issue.2 , pp. 167-174
    • Matthews, D.R.1    Charbonnel, B.H.2    Hanefeld, M.3    Brunetti, P.4    Schernthaner, G.5
  • 25
    • 77955900074 scopus 로고    scopus 로고
    • Effects of thiazolidinediones and sulfonylureas in patients with diabetes
    • Derosa G, Maffioli P. Effects of thiazolidinediones and sulfonylureas in patients with diabetes. Diabetes Technol Ther. 2010;12(6):491-501.
    • (2010) Diabetes Technol Ther , vol.12 , Issue.6 , pp. 491-501
    • Derosa, G.1    Maffioli, P.2
  • 26
    • 0032511583 scopus 로고    scopus 로고
    • Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group
    • Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837-853.
    • (1998) Lancet , vol.352 , Issue.9131 , pp. 837-853
  • 27
    • 84859879074 scopus 로고    scopus 로고
    • Use of concomitant glucose-lowering therapies and associated treatment results observed in clinical trials of twice-daily exenatide
    • Pencek R, Brunell SC, Li Y, Hoogwerf BJ, Malone J. Use of concomitant glucose-lowering therapies and associated treatment results observed in clinical trials of twice-daily exenatide. Endocr Pract. 2012;18(2):227-237.
    • (2012) Endocr Pract , vol.18 , Issue.2 , pp. 227-237
    • Pencek, R.1    Brunell, S.C.2    Li, Y.3    Hoogwerf, B.J.4    Malone, J.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.